Explore India's leading biotech companies driving innovation in healthcare and beyond.
India's biotech industry, fueled by initiatives like "Make in India," spans biopharmaceuticals, bio-agriculture, and bioinformatics, with a market value expected to surpass $150 billion by 2025.
Biocon Ltd., headquartered in Bangalore, specializes in biopharmaceuticals, biosimilars, and research-driven therapies for diabetes and oncology. Market Cap: ₹44,001.99 Crore (as of Dec 31, 2024). Source: NSE.
Concord Biotech Ltd. (Market Cap: ₹23,538.65 Cr) specializes in fermentation-based biopharmaceuticals, providing APIs for immunosuppressants and oncology. Based in Ahmedabad. Data as of 31st Dec 2024. NSE.
Sun Pharma Advanced Research (Market Cap: ₹6,487.19 Cr), based in Mumbai, focuses on new chemical entities and innovative drug delivery systems to enhance therapeutic efficacy. Data as of 31st Dec 2024. Source: NSE.
Windlas Biotech Ltd. (Market Cap: ₹2,152.73 Cr), based in Dehradun, specializes in contract development and manufacturing, supporting global pharma brands with high-quality formulations. Data as of 31st Dec 2024. Source: NSE.
Market Cap: ₹55.11 Crore Based in Hyderabad, Vivo Biotech is a leader in preclinical contract research and biologics development, catering to global pharmaceutical companies. Data as of 31st December 2024. Source - NSE
Vivo Biotech Ltd. (Market Cap: ₹55.11 Cr), based in Hyderabad, is a leader in preclinical contract research and biologics development, serving global pharmaceutical companies. Data as of 31st Dec 2024. Source: NSE.
Summary India's biotech sector is thriving, fueled by innovation, R&D, and supportive policies. Companies like Biocon, Concord Biotech, and Windlas Biotech are leading this charge with groundbreaking contributions. Data as of 31st December 2024. Source NSE